News

Jacques Grosset Interview

Dr. Jacques Grosset
Dr. Jacques Grosset

Dr. Jacques Grosset’s biography is excerpted from his staff page on the Johns Hopkins Medicine website.

Since the beginning of my professional life I have been involved in research to improve the control of tuberculosis, mainly by improving treatment of tuberculosis and preventing the development of drug resistance.

Tuberculosis was a leading cause of death in industrialized countries when I started my medical studies.

During the past 45 years, I have participated in the development of nearly all new drug regimens used for tuberculosis and a number of other mycobacterial diseases, namely leprosy, M. avium complex infection in HIV-infected persons, and M. ulcerans infection (Buruli ulcer). Using the murine experimental model, I directed the development of an antibiotic regimen that led to the first clinical that demonstrated the efficacy of this treatment for Buruli ulcer. I also participated in the design and evaluation of this trial. At present, my primary involvement is in the use of the mouse model to investigate the efficacy of new drugs and new drug combinations in human diseases caused by mycobacteria for improving both the efficacy of treatment and the implementation of Directly Observed Therapy (DOT).

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...